[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100435571":3},{"organization":4,"armGroups":7,"interventions":14,"overallOfficials":21,"centralContacts":26,"locations":36,"responsibleParty":55,"collaborators":20,"id":58,"slug":59,"hasResults":60,"nctId":61,"briefTitle":62,"officialTitle":63,"acronym":20,"eligibilityCriteria":64,"healthyVolunteers":60,"sex":65,"minAge":66,"maxAge":67,"enrollmentInfo":68,"targetDuration":20,"studyType":71,"phases":72,"briefSummary":74,"conditions":75,"keywords":20,"overallStatus":38,"whyStopped":20,"lastUpdateSubmitDate":77,"lastUpdatePostDateStruct":78,"startDateStruct":81,"completionDateStruct":83,"leadSponsor":85,"locationsCount":86},{"fullName":5,"class":6},"Hunan Province Tumor Hospital","OTHER",[8],{"label":9,"type":10,"description":11,"interventionNames":12},"Arm A","EXPERIMENTAL","Treatment arm",[13],"Drug: JS201 combine with Lenvatinib",[15],{"type":16,"name":17,"description":18,"armGroupLabels":19,"otherNames":20},"DRUG","JS201 combine with Lenvatinib","JS201 300mg i.v Q2wLenvatinib 8mg po. Qd",[9],null,[22],{"name":23,"affiliation":24,"role":25},"Yongchang Zhang, MD","Hunan Cancer Hospital","PRINCIPAL_INVESTIGATOR",[27,32],{"name":23,"role":28,"phone":29,"phoneExt":30,"email":31},"CONTACT","+8613873123436","7+861383123436","zhangyongchang@csu.edu.cn",{"name":33,"role":28,"phone":34,"phoneExt":29,"email":35},"Nong Yang, MD","+8613055193557","yangnong0217@163.com",[37],{"facility":24,"status":38,"city":39,"state":40,"zip":41,"country":42,"countryCode":43,"cosmosGeoPoint":44,"geoPoint":49,"contacts":50},"RECRUITING","Changsha","Hunan","410013","China","CN",{"type":45,"coordinates":46},"Point",[47,48],112.97087,28.19874,{"lat":48,"lon":47},[51,53],{"name":33,"role":28,"phone":52,"phoneExt":20,"email":35},"+86 731 89762323",{"name":23,"role":28,"phone":54,"phoneExt":20,"email":31},"+86 731 89762321",{"type":25,"investigatorFullName":56,"investigatorTitle":57,"investigatorAffiliation":5,"oldNameTitle":20,"oldOrganization":20},"Yongchang Zhang","Director, Head of Medical Oncology, Principal Investigator, Clinical Professor","100435571","phase-2-js-201-combined-with-lenvatinib-in-the-treatment-of-small-cell-lung-cancer-100435571",false,"NCT04951947","JS-201 Combined With Lenvatinib in the Treatment of Small-cell Lung Cancer","A Prospective, Single-arm Phase II Clinical Study to Evaluate the Efficacy and Safety of JS-201 Combined With Lenvatinib in the Treatment of Small-cell Lung Cancer With Previous Chemotherapy Combined With PD-L1 Failure","Inclusion Criteria:\n\n* 1\\. The imaging diagnosis is the extensive stage of SCLC\n* 2\\. The patient failed first-line EC+PD-L1 treatment\n* 3 PS 0-1\n\nExclusion Criteria:\n\n* 1\\. Diagnosed as non-small cell lung cancer\n* 2\\. Women during pregnancy\n* 3\\. Patients with symptomatic brain metastases\n* 4\\. PS≥2","ALL","18 Years","75 Years",{"count":69,"type":70},30,"ESTIMATED","INTERVENTIONAL",[73],"PHASE2","This is a prospective, single-arm phase II clinical study to evaluate the efficacy and safety of JS-201 combined with lenvatinib in the treatment of small-cell lung cancer that has failed previous chemotherapy combined with PD-L1. The primary observational endpoint is ORR, and the secondary observational endpoint is PFS, OS. The intervention mode is JS201 300mg i.v Q2w, lenvatinib 8mg po. Qd.",[76],"Small-cell Lung Cancer","2024-09-17",{"date":79,"type":80},"2024-09-19","ACTUAL",{"date":82,"type":80},"2023-06-01",{"date":84,"type":70},"2025-06-01",{"name":5,"class":6},1]